Markets
Young woman sitting in the office at the table with a laptop, using the phone and looking worriedly at the camera, raising her hands in frustration
Confusion reigns.

The US stock market is going up despite so many stocks going down

A prelude to more drama?

Luke Kawa

Everyone and their mother is – or should be – talking about low breadth in the US stock market.

Whether it’s Nvidia breaking away from its peers, or the unprecedented divergence between the equal-weighted and market-cap versions of the S&P 500, the price action over the past month has been remarkable and unique.

We haven’t had a four-week span where the US stock market has gone up so much with so many stocks within the market going down, based on data going back to 2002.

(The S&P 500 cumulative advance-decline line is the running total of the number of stocks that rise versus fall each day).

The cumulative advance decline line is down by over 1000 during a period in which the S&P 500 rose 2.4%. There really isn’t anything close in the past 20+ years – not even if you chop each of these moves in half. 

History isn’t really instructive in navigating these waters. There’s an inherent tendency to think that gaps like these must resolve themselves: either by megacaps correcting downward, or by the rest of the index zooming higher while those names take a breather.

But even though investors haven’t faced a market particularly like this, its closest cousin (still a distant relative) happened just last May, when the S&P 500 rose 0.9% in a four-week span while the cumulative A/D line contracted by nearly 1000. 

The “why” and “how” looks similar now to then, in broad strokes.

Nvidia effectively kicked off the AI boom in May 2023, and more recently has reaffirmed this as a catalyst for continued eye-popping operating performance. Meanwhile, the Citi US economic surprise index, which measures the extent to which incoming data are exceeding or falling short of economists’ expectations, dipped into negative territory in mid-May 2023. It has dropped sharply over the past two months and is now at -20.

During that four-week span ending May 26, 2023, the S&P 500 outperformed its equal-weight counterpart by nearly 4%. And the gap didn’t really close – not violently, at least. The equal-weight S&P just rose a little more than the market-cap version over the next four and eight weeks. 

Two things that are still true of the investment landscape: profit growth is still expected to be hyper-concentrated in the mega-caps (at least for the next couple quarters). And there’s little worry that the US economy is falling off a cliff; 2024 GDP growth estimates have been stable at 2.4% for the past six weeks.

If both those continue to hold, the dramatic divergence we’ve witnessed in the past month need not end with a bang. Just because we’re in uncharted waters doesn’t mean we’re heading for a waterfall. It could end up being a lazy river.

More Markets

See all Markets
markets

Space stocks rip amid speculation on Altman joining race

Space stocks AST SpaceMobile, Planet Labs, and Rocket Lab all soared Thursday amid a recovery in the high-beta momentum class of shares coveted by some retail traders.

(High-beta momo stocks are basically shares that have been on a winning streak for a while, and tend to go up a lot more than the overall market on positive days. Goldman Sachs includes all three of the aforementioned space stocks in its themed basket of such shares.)

There’s little other fundamental news out there on the companies themselves.

But a Wall Street Journal report that OpenAI impresario Sam Altman has been toying with the idea of entering the space industry, potentially standing up a rival to Tesla CEO Elon Musk’s Starlink satellite service, may also be contributing.

As we’ve mentioned elsewhere, sometimes these stocks seem to trade on a what’s-bad-for-the-Musk-empire-is-good-for-us-and-vice-versa vibe.

markets

Intel sinks on news it will hang on to networking unit

Intel dropped in early trading Thursday after it disclosed plans to retain ownership of its networking unit following a strategic review of operations.

The unit, known as NEX, makes products like infrastructure processors, which do needed “housekeeping” tasks like running security checks, thereby freeing core Intel CPUs to do the higher-value operations. It also produces switches and controllers that manage and direct the flow of data to CPUs.

markets

Quantum computing stocks soar on return of bullish options bets

The calendar says December, but the price action is starting to look a lot more like September to me:

Quantum computing companies IonQ, Rigetti Computing, and D-Wave Quantum are all up at least 7% as of 11:04 a.m. ET, buoyed by a wave of bullish options activity.

  • Nearly 50,000 calls in IonQ have already changed hands, well above the 20-day average for a full session, with activity concentrated in strikes from $50 to $55 in contracts that expire between Friday and mid-January. Its put/call ratio is near 0.2, versus an average of over 1 for the past 20 sessions.

  • More than 65,000 calls have traded in Rigetti, a hair shy of its full 20-day average. Like IonQ, options activity has a bullish tilt, with a put/call ratio of about 0.7 versus a 20-day average of roughly 1.2.

  • D-Wave, which received positive commentary from Evercore ISI on Wednesday, isn’t seeing call activity as elevated as its peers, but the options action is also very skewed toward the bull side, with a put/call ratio of less than 0.3 versus a 20-session average of 0.7.

Pure-play quantum computing stocks nearly doubled from late August to late September amid heavy options market activity thanks to reports on government support for the sector, M&A activity, tech breakthroughs, and a flurry of price target hikes by Wall Street.

markets

Hims announces acquisition of Canadian telehealth firm Livewell

Hims & Hers rose in early trading after it announced its acquisition of Livewell, a Canadian telehealth company, marking its official entrance to that market.

The company announced in July that it would expand into Canada by 2026, taking advantage of the patent expiry for semaglutide, the active ingredient in Novo Nordisk’s blockbuster GLP-1s, Ozempic and Wegovy. Hims said Thursday that it would do that through an all-cash acquisition of Livewell.

Novo’s patent on semaglutide is set to expire in Canada in January. It would be the first time generics for the blockbuster GLP-1 drugs are available anywhere, and generic drugmaker Sandoz International has already announced plans to make copies of the drug. In the US, Hims sells copycat versions of Novo’s drugs, which has led to conflict between the companies.

On Wednesday, Hims announced that it would purchase YourBio, a device that uses “bladeless microneedles thinner than an eyelash” to collect blood samples, in another all-cash deal. According to its latest quarterly filing, the company had $345.8 million in cash and cash equivalents.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.